NASDAQ$MDLN
Medline Inc · Q2 2026 earnings
Q2 2026 earnings · · Before market open
Briefing
Medline Inc reported second quarter 2026 results with net sales growth of 11.6% and net income decline of 58.3%.
Medline Inc delivered Q2 2026 net sales of $7.685 billion, up 11.6% year-over-year, driven by existing customer growth and new signings, partially offset by $89 million in IEEPA tariff customer repayments. Net income fell to $139 million due to $336 million in losses from the Tracy distribution center fire and higher expenses, while Adjusted EBITDA rose 13.4% to $1.06 billion benefiting from tariff refunds. The company updated full-year 2026 Organic Sales guidance to 9.0%-10.0% and Adjusted EBITDA to $3.3-$3.4 billion.
- Q2 net sales reached $7.685 billion, an 11.6% increase, with Organic Sales up 11.5%.
- Net income dropped 58.3% to $139 million primarily due to fire-related losses at the Tracy facility.
- Adjusted EBITDA grew 13.4% to $1.06 billion, supported by $243 million in net IEEPA tariff benefits.
- Full-year 2026 guidance was updated to 9.0%-10.0% Organic Sales growth and $3.3-$3.4 billion Adjusted EBITDA.
Headline financials
Revenue & EPS history
Medline Inc · Revenue · Quarterly
$7.69B
Revenue by segment
Medline Inc · $7.69B total across 2 segments · Q2 2026
- Supply Chain Solutions$4.15B—53.9%
- Medline Brand$3.54B—46.1%
Forward guidance
Full year 2026 Organic Sales guidance updated to 9.0% to 10.0% and Adjusted EBITDA guidance to $3.3 billion to $3.4 billion.
Tailwinds
- Strong existing and new customer demand driving higher Organic Sales outlook
Headwinds
- Higher inflationary pressure from Middle East conflict
- Increased operational investments and quality remediation efforts
- Retail channel softness
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 2 quarterly earnings reports
-5.5%
Avg return
Earnings day
-10.8%
Avg return
5 days after
-21.6%
Avg return
30 days after
0%
0 / 2 earnings
Positive
-3.6%
Q4 2025
Best reaction
-7.3%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | -7.3% | -13.4% | -25.9% | |
| Q4 2025 | -3.6% | -8.3% | -17.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro